Latanoprost

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Latanoprost: instructions for use and reviews

1. Release form and composition
2. Pharmacological properties
3. Indications for use
4. Contraindications
5. Method of application and dosage
6. Side effects
7. Overdose
8. Special instructions
9. Application during pregnancy and lactation
10. Use in childhood
11. Drug interactions
12. Analogs
13. Terms and conditions of storage
14. Terms of dispensing from pharmacies
15. Reviews
16. Price in pharmacies

Latin name: Latanoprost

ATX code: S01EE01

Active ingredient: latanoprost (Latanoprost)

Manufacturer: Kern Pharma S. L. (Kern Pharma SL) (Spain)

Description and photo update: 2019-24-07

Latanoprost is an antiglaucoma drug, a synthetic analogue of prostaglandin F _2-alpha.

Release form and composition

Latanoprost is available in the form of eye drops 0.005%: a clear liquid without color (2.5 ml in dropper bottles, 1 bottle in a cardboard box) and instructions for using Latanoprost.

1 ml drops contain:

active substance: latanoprost - 0.05 mg;
auxiliary components: sodium hydrogen phosphate, sodium dihydrogen phosphate, benzalkonium chloride, sodium chloride, purified water.

Pharmacological properties

Pharmacodynamics

Latanoprost is an antiglaucoma drug that lowers intraocular pressure. Its active substance is a synthetic analogue of prostaglandin F _2-alpha and a selective FP receptor agonist. The clinical effect of latanoprost is realized as a result of increased outflow of aqueous humor, mainly along the uveoscleral pathway. After instillation of the drug, a decrease in intraocular pressure occurs after 3-4 hours, the maximum effect is achieved after 8-12 hours. Duration of action - at least 24 hours.

Does not affect the production of aqueous humor and the blood-ophthalmic barrier.

Pharmacokinetics

After topical application, latanoprost is well absorbed through the cornea, where it is hydrolyzed to biologically active acid. In aqueous humor, its maximum concentration is reached after 2 hours.

Latanoprost acid metabolism occurs mainly in the liver with the formation of 1,2-dinor and 1,2,3,4-tetranor metabolites. The biological activity of the main metabolites is weak or completely absent. It is almost not metabolized in the tissues of the eye.

It is possible to excrete latanoprost and its metabolites in breast milk.

The half-life is 17 minutes. It is excreted through the kidneys.

Indications for use

The use of Latanoprost is indicated for open-angle glaucoma, ocular hypertension.

Contraindications

Absolute:

breast-feeding;
age up to 18 years;
hypersensitivity to the components of the drug.

Caution should be observed in patients with aphakia, pseudoaphakia with rupture of the posterior lens capsule, in inflammatory, neovascular or congenital glaucoma, and in the presence of risk factors for macular edema.

During pregnancy, Latanoprost can only be used under medical supervision in cases where the expected therapeutic effect for the mother is higher than the potential threat of side effects in the fetus.

Latanoprost, instructions for use: method and dosage

Drops are injected into the conjunctival sac of the affected eye, preferably in the evening.

Recommended dosage: 1 drop, 1 time per day.

Do not double the next dose if you accidentally skip the previous instillation of the drug.

Side effects

on the part of the organ of vision: burning, itching, sensation of pain, tingling, sand and / or foreign body in the eyes, blepharitis, conjunctival hyperemia, eyelid edema, increased iris pigmentation, temporary punctate erosion of the epithelium, conjunctivitis, edema and erosion of the cornea, keratitis, uveitis (iritis), macular edema (including cystoid), blurred vision; eye irritation caused by a change in the direction of eyelash growth; thickening, lengthening, increase in the number and aggravation of eyelash and vellus hair pigmentation;
from the respiratory system: shortness of breath, acute attacks of bronchial asthma, exacerbation of the disease in patients with a history of bronchial asthma;
from the nervous system: headache, dizziness;
from the musculoskeletal system: pain in the muscles and / or joints;
dermatological reactions: darkening of the skin and local skin reactions from the eyelids, rash;
others: chest pains of a non-specific nature.

Overdose

Symptoms: irritation of the mucous membrane of the eye, conjunctival hyperemia, episclera hyperemia.

Treatment: the appointment of symptomatic therapy.

special instructions

When prescribing Latanoprost, the doctor should inform the patient about a possible change in eye color while using the drug. The change in eye color occurs gradually due to an increase in the amount of brown pigment in the iris, due to an increase in the melanin content in the stromal melanocytes of the iris. In patients with blue-brown, gray-brown, green-brown or yellow-brown color of the iris, the pigmentation is more pronounced. Brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris of the affected eye, with a more intense brown color occurring in the entire iris or only parts of it. In patients with intensive changes in eye pigmentation, treatment with Latanoprost should be discontinued.

In patients with uniform eye coloration (for example, brown, blue, gray or green), changes in eye color after prolonged use of the drug (within 2 years) are very rare.

The developed change in eye color can be irreversible. This should be taken into account in patients using drops to treat only one eye, due to the existing risk of developing heterochromia - a different color of the iris in the right and left eyes.

Changes in the structure, color and length of eyelashes disappear after stopping treatment.

Patients with contact lenses are advised to remove the lenses before each procedure for instilling eye drops and insert them no earlier than 15 minutes after instillation.

Influence on the ability to drive vehicles and complex mechanisms

If, against the background of the use of Latanoprost, the patient develops a transient blurred vision, then during the period of its recovery it is recommended to avoid driving or using complex mechanisms.

Application during pregnancy and lactation

The use of Latanoprost during gestation is allowed in cases where the expected therapeutic effect for the mother exceeds the threat of developing adverse events in the fetus, and only under medical supervision.

It is contraindicated to prescribe the drug while breastfeeding. In the presence of clinical indications during lactation, breastfeeding should be discontinued.

Pediatric use

The use of Latanoprost is contraindicated for the treatment of patients under the age of 18 years.

Drug interactions

It should be borne in mind that with the simultaneous use of another analogue of prostaglandins, a paradoxical increase in intraocular pressure may occur.

Established pharmaceutical incompatibility of latanoprost with eye drops containing thiomersal. When combined with such agents, a solid precipitate (precipitation) is formed in the solution during a chemical reaction.

When combined therapy with other drugs in the form of eye drops, the interval between instillations should be at least 5 minutes.

Analogs

Latanoprost analogs are: Latanoprost-Teva, Glaumax, Latanol, Glauprost, Ksalatan, Xalatamax, Lanotan, Prolatan, Trilactan.

Terms and conditions of storage

Keep out of the reach of children.

Store at 2–8 ° C in a dark place, do not freeze.

Shelf life is 2 years.

Once opened, the contents of the vial are stable for 28 days at storage temperatures up to 25 ° C.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Latanoprost

There are no reviews of Latanoprost.

Price for Latanoprost in pharmacies

Due to the lack of the drug in the pharmacy network, the price for Latanoprost has not been established.

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!